← Leaderboards
Arun P. Wiita
University Of California, San Francisco
$7,077,627
Attributed
$9,424,462
Total exposure
9
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2014–25$2.5M$1.9M$1.3M$625K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,424,462 · 9
By mechanism
R01$5,964,629 · 4
DP2$1,890,000 · 1
K08$684,026 · 1
R21$424,307 · 1
R43$300,000 · 1
R03$161,500 · 1
Top collaborators
- Robert Richard Flavell5 shared
- Lan Huang2 shared
- Guy Dipierro1 shared
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Robert Richard Flavell$4,877,416
- Edward Murphy$15,415,562
- Rachel O'Keefe$77,368
- Stephanie Redmond$532,021
- Renata Constance Gallagher$323,000
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsCellsMultiple MyelomaProteomicsHematopoietic NeoplasmsSignal TransductionBaseMass Spectrum AnalysisProteinsHematologic NeoplasmsNeoplastic CellPharmaceutical PreparationsPre-ClinicalComplexCell LineRelapseAwardLeadInvestigationPathway InteractionsResistancePlasma CellsApoptosisDiagnosis
Grant awards (25)
Selective treatment of acute myeloid leukemia with radioimmunotherapies targeting the active conformation of integrin beta-2$678,101
R01 · FY2025 · CA · contact PI
Development of CD46 theranostics for imaging and treatment of multiple myeloma$670,219
R01 · FY2025 · CA
Structural surfaceomics to probe conformation-selective immunotherapy targets$531,377
R01 · FY2025 · CA · contact PI
Development of CD46 theranostics for imaging and treatment of multiple myeloma$636,706
R01 · FY2024 · CA
Structural surfaceomics to probe conformation-selective immunotherapy targets$550,255
R01 · FY2024 · CA · contact PI
Development of CD46 theranostics for imaging and treatment of multiple myeloma$656,800
R01 · FY2023 · CA
Development of CD46 theranostics for imaging and treatment of multiple myeloma$670,212
R01 · FY2022 · CA
Exploiting myeloma proteome remodeling to extend proteasome inhibitor efficacy$278,183
R01 · FY2022 · CA · contact PI
Structural Surfaceomics: A Strategy for Immunotherapy Target Discovery$221,071
R21 · FY2022 · CA · contact PI
Exploiting myeloma proteome remodeling to extend proteasome inhibitor efficacy$85,291
R01 · FY2022 · CA · contact PI
ClinTAD: A Tool for Improving Clinical CNV Interpretation$80,750
R03 · FY2022 · HD · contact PI
Exploiting myeloma proteome remodeling to extend proteasome inhibitor efficacy$284,107
R01 · FY2021 · CA · contact PI
Structural Surfaceomics: A Strategy for Immunotherapy Target Discovery$203,236
R21 · FY2021 · CA · contact PI
ClinTAD: A Tool for Improving Clinical CNV Interpretation$80,750
R03 · FY2021 · HD · contact PI
Exploiting myeloma proteome remodeling to extend proteasome inhibitor efficacy$55,283
R01 · FY2021 · CA · contact PI
Exploiting myeloma proteome remodeling to extend proteasome inhibitor efficacy$292,288
R01 · FY2020 · CA · contact PI
Immuno Oncology Product for Multiple Myeloma: g-NK Cellular Therapy to Optimize Monoclonal Antibody Efficacy in Treating Multiple$300,000
R43 · FY2019 · CA
Exploiting myeloma proteome remodeling to extend proteasome inhibitor efficacy$283,519
R01 · FY2019 · CA · contact PI
Exploiting myeloma proteome remodeling to extend proteasome inhibitor efficacy$292,288
R01 · FY2018 · CA · contact PI
Global Assessment of Myeloma Response to Chemotherapy$112,711
K08 · FY2018 · CA · contact PI
Global Assessment of Myeloma Response to Chemotherapy$112,711
K08 · FY2017 · CA · contact PI
In vivo monitoring of oxidative protein folding through time-resolved quantitative mass spectrometry$1,890,000
DP2 · FY2016 · GM · contact PI
Global Assessment of Myeloma Response to Chemotherapy$152,868
K08 · FY2016 · CA · contact PI
Global Assessment of Myeloma Response to Chemotherapy$152,868
K08 · FY2015 · CA · contact PI
Global Assessment of Myeloma Response to Chemotherapy$152,868
K08 · FY2014 · CA · contact PI